Cofactor Genomics

Executive Summary

Cofactor Genomics is a privately held biotechnology company headquartered in St. Louis, Missouri, that specializes in RNA sequencing (RNA-Seq) for predictive diagnostics. The company's lead product, OncoPrism, is a novel diagnostic assay designed to predict patient responses to immunotherapy in oncology. By leveraging RNA analysis, OncoPrism aims to address a critical unmet need in precision oncology: identifying which patients are most likely to benefit from immunotherapies, thereby reducing unnecessary treatments and improving outcomes. The company positions itself at the forefront of RNA-based diagnostics, with a technology platform that has the potential to be applied across multiple cancer types and therapeutic areas. Cofactor Genomics is currently conducting a large-scale national clinical trial to validate the OncoPrism assay's predictive capabilities in real-world settings. Successful completion of this trial and subsequent regulatory approvals could position the company as a key player in the rapidly growing liquid biopsy and precision diagnostics market. While the company remains private and has not disclosed funding details, its technology has attracted attention from oncologists and payers seeking cost-effective tools to optimize treatment decisions. The near-term outlook hinges on clinical data readouts and potential partnerships or regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Completion of Large-Scale National Clinical Trial for OncoPrism70% success
• Q4 2026FDA Breakthrough Device Designation for OncoPrism60% success
• 2027Strategic Partnership for Commercialization50% success